

## DAFTAR PUSTAKA

1. Simpson EL, Leung DYM, Eichenfield LF, Boguniewicz M. Atopic Dermatitis. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., editors. Fitzpatrick's Dermatology, 9e [Internet]. New York, NY: McGraw-Hill Education; 2019.
2. Nutten S. Atopic dermatitis: Global epidemiology and risk factors. *Ann Nutr Metab*. 2015;66:8–16.
3. Yang L, Fu J, Zhou Y. Research Progress in Atopic March. *Front Immunol*. 2020;11(August):1–11.
4. Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. *Clin Dermatol* [Internet]. 2018;36(5):595–605.
5. Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): A systematic review and meta-analysis. *J Am Acad Dermatol* [Internet]. 2016;75(4):681-687.e11.
6. Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A global synthesis. *Allergol Immunopathol (Madr)* [Internet]. 2013;41(2):73–85.
7. Kelompok Studi Dermatologi Anak Indonesia. Panduan Diagnosis dan Tatalaksana Dermatitis Atopik di Indonesia. 2014. 1–41 p.
8. Drucker AM. Atopic dermatitis: Burden of illness, quality of life, and associated complications. *Allergy Asthma Proc*. 2017;38(1):3–8.
9. Lee BW, Detzel PR. Treatment of Childhood Atopic Dermatitis and Economic Burden of Illness in Asia Pacific Countries. *Ann Nutr Metab* [Internet]. 2015;66(Suppl. 1):18–24.
10. Tsai TF, Rajagopalan M, Chu CY, Encarnacion L, Gerber RA, Santos-Estrella P, et al. Burden of atopic dermatitis in Asia. *J Dermatol*. 2019;46(10):825–34.
11. Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI). Panduan Praktik Klinis Bagi Dokter Spesialis Kulit dan Kelamin di Indonesia. Jakarta : PERDOSKI. 2017.
12. Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials : long- term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. *BMC Pediatr* [Internet]. 2016;1–15.
13. Paller AS, Block J, Simpson EL, Eczema N, Task A. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. *J Am Dermatology* [Internet]. 2015;72(3):541-549.e2.
14. El-wahed AAA, Khalifa SAM, Elashal MH, Musharraf SG, Saeed A, Khatib A, et al. Cosmetic Applications of Bee Venom. *Toxins (Basel)*.

- 2021;13.
15. Zhang S, Liu Y, Ye Y, Wang XR, Lin LT, Xiao LY, et al. Bee venom therapy: Potential mechanisms and therapeutic applications. *Toxicon* [Internet]. 2018;148:64–73.
  16. Kim H, Park SY, Lee G. Potential therapeutic applications of bee venom on skin disease and its mechanisms: A literature review. *Toxins (Basel)*. 2019;11(7):4–6.
  17. You CE, Moon SH, Lee KH, Kim KH, Park CW, Seo SJ, et al. Effects of emollient containing bee venom on atopic dermatitis: A double-blinded, randomized, base-controlled, multicenter study of 136 patients. *Ann Dermatol*. 2016;28(5):593–9.
  18. Gu H, Han SM, Park KK. Therapeutic effects of apamin as a bee venom component for non-neoplastic disease. *Toxins (Basel)*. 2020;12(3):1–17.
  19. Gu H, Kim WH, An HJ, Kim JY, Gwon MG, Han SM, et al. Therapeutic effects of bee venom on experimental atopic dermatitis. *Mol Med Rep*. 2018;18(4):3711–8.
  20. Kim Y, Lee YW, Kim H, Chung DK. Bee venom alleviates atopic dermatitis symptoms through the upregulation of decay-accelerating factor (DAF/CD55). *Toxins (Basel)*. 2019;11(5).
  21. An HJ, Kim JY, Kim WH, Gwon MG, Gu HM, Jeon MJ, et al. Therapeutic effects of bee venom and its major component, melittin, on atopic dermatitis in vivo and in vitro. *Br J Pharmacol*. 2018;175(23):4310–24.
  22. Jung KH, Baek H, Kang M, Kim N, Lee SY, Bae H. Bee venom phospholipase A2 ameliorates house dust mite extract induced atopic dermatitis like skin lesions in mice. *Toxins (Basel)*. 2017;9(2).
  23. Bylund S, Von Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: A systematic review. *Acta Derm Venereol*. 2020;100(100-year theme Atopic dermatitis):320–9.
  24. Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. *Allergy Eur J Allergy Clin Immunol*. 2018;73(6):1284–93.
  25. Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. *Ann Allergy, Asthma Immunol* [Internet]. 2021;126(4):417-428.e2.
  26. Gustia R, Yenny SW, Octari S. Karakteristik penyakit kulit pada anak di poliklinik kulit dan kelamin RSUP. Dr. M. Djamil Padang periode 2016-2018. *J Kedokt Syiah Kuala*. 2020;20(3):143–6.
  27. Ng YT, Chew FT. A systematic review and meta-analysis of risk factors associated with atopic dermatitis in Asia. *World Allergy Organ J* [Internet]. 2020;13(11):100477.

28. Gao X, Yan Y, Zeng G, Sha T, Liu S, He Q, et al. Influence of prenatal and early-life exposures on food allergy and eczema in infancy: A birth cohort study. *BMC Pediatr*. 2019;19(1):1–9.
29. Abolhasani R, Araghi F, Tabary M, Aryannejad A, Mashinchi B, Robati RM. The impact of air pollution on skin and related disorders: A comprehensive review. *Dermatol Ther*. 2021;34(2).
30. Bonamonte D, Filoni A, Vestita M, Romita P, Foti C, Angelini G. The Role of the Environmental Risk Factors in the Pathogenesis and Clinical Outcome of Atopic Dermatitis. *Biomed Res Int*. 2019;2019.
31. Chung J, Simpson EL. The socioeconomics of atopic dermatitis. *Ann Allergy, Asthma Immunol* [Internet]. 2019;122(4):360–6.
32. Chiesa Fuxench ZC. Atopic Dermatitis: Disease Background and Risk Factors. *Adv Exp Med Biol*. 2017;1027:11–9.
33. Boer M, Duchnik E, Maleszka R, Marchlewicz M. Structural and biophysical characteristics of human skin in maintaining proper epidermal barrier function. *Postep Dermatologii i Alergol*. 2016;33(1):1–5.
34. Nakahara T, Kido-Nakahara M, Tsuji G, Furue M. Basics and recent advances in the pathophysiology of atopic dermatitis. *J Dermatol*. 2021;48(2):130–9.
35. Furue M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic implications in atopic dermatitis. *Int J Mol Sci*. 2020;21(15):1–25.
36. Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. *Int J Mol Sci*. 2020;21(8):1–14.
37. Lyons JJ, Milner JD, Stone KD. Atopic Dermatitis in Children: Clinical Features, Pathophysiology, and Treatment. *Immunol Allergy Clin North Am* [Internet]. 2015;35(1):161–83.
38. Alsabbagh M, Ismaeel A. The role of cytokines in atopic dermatitis: a breakthrough in immunopathogenesis and treatment. *Acta Dermatovenerologica Alpina, Pannonica Adriat*. 2022;31(1):13–31.
39. Mandlik DS, Mandlik SK. Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies. *Immunopharmacol Immunotoxicol* [Internet]. 2021;43(2):105–25.
40. Ahn C, Huang W. Clinical Presentation of Atopic Dermatitis. *Adv Exp Med Biol*. 2017;1027:39–46.
41. Huang E, Ong PY. Severe atopic dermatitis in children. *Pediatr Allergy Immunol* [Internet]. 2018 Dec 31;14(4):376–80.
42. Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. *J Am Acad Dermatol* [Internet]. 2019;80(2):390–401.



43. Chan AR, Sandhu VK, Drucker AM, Fleming P, Lynde CW. Adult-Onset Atopic Dermatitis: Presentations and Progress. *J Cutan Med Surg.* 2020;24(3):267–72.
44. Saeki H, Nakahara T, Tanaka A, Kabashima K, Sugaya M, Murota H, et al. Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016. *J Dermatol.* 2016;43(10):1117–45.
45. Wollenberg A, Werfel T, Ring J, Ott H, Gieler U, Weidinger S. Atopic Dermatitis in Children and Adults Diagnosis and Treatment. *Dtsch Arztebl Int.* 2023;120(13):224–34.
46. Čelakovská J, Bukač J. The severity of atopic dermatitis and analysis of the food hypersensitivity reactions. *Food Agric Immunol [Internet].* 2015;26(6):896–908.
47. Kulthanan K, Tuchinda P, Nitiyarom R, Chunharas A, Chantaphakul H, Aunhachoke K, et al. Clinical practice guidelines for the diagnosis and management of atopic dermatitis. *Asian Pacific J Allergy Immunol.* 2021;39(3):145–55.
48. Chow S, Seow CS, Dizon MV, Godse K, Foong H, Chan V, et al. A clinician's reference guide for the management of atopic dermatitis in Asians. *Asia Pac Allergy.* 2018;8(4):e41.
49. Farmer WS, Marathe KS. Atopic Dermatitis: Managing the Itch. *Adv Exp Med Biol.* 2017;1027:161–77.
50. Purnamawati S, Indrastuti N, Danarti R, Saefudin T. The role of moisturizers in addressing various kinds of dermatitis: A review. *Clin Med Res.* 2017;15(3–4):75–87.
51. Eddin LB, Jha NK, Goyal SN, Agrawal YO, Subramanya SB, Bastaki SMA, et al. Health Benefits, Pharmacological Effects, Molecular Mechanisms, and Therapeutic Potential of  $\alpha$ -Bisabolol. *Nutrients.* 2022;14(7).
52. Chandan N, Rajkumar JR, Shi VY, Lio PA. A new era of moisturizers. *J Cosmet Dermatol.* 2021;20(8):2425–30.
53. Wollenberg A, Barbarot S, Bieber T, Deleuran M, Gieler U. Consensus-based European guidelines for treatment of atopic eczema ( atopic dermatitis ) in adults and children : part I. 2018;657–82.
54. Mehta AB, Nadkarni NJ, Patil SP, Godse K V, Gautam M, Agarwal S. Topical corticosteroids in dermatology. *Indian J Dermatol Venereol Leprol.* 2016;82(4):371–8.
55. Hong CH, Gooderham M, Bissonnette R. Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis. *J Cutan Med Surg.* 2019;23(4\_suppl):5S-10S.
56. Ong PY, Leung DYM. Bacterial and Viral Infections in Atopic Dermatitis: a Comprehensive Review. *Clin Rev Allergy Immunol [Internet].* 2016;51(3):329–37.

57. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. *J Eur Acad Dermatology Venereol*. 2018;32(6):850–78.
58. Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, et al. Update “Systemic treatment of atopic dermatitis” of the S2k-guideline on atopic dermatitis. *JDDG - J Ger Soc Dermatology*. 2021;19(1):151–68.
59. Yarbrough K, Simpson E. Atopic Dermatitis: Complications. *Harper’s Textb Pediatr Dermatology*. 2020;245–52.
60. Hsu JI, Pflugfelder SC, Kim SJ. Ocular complications of atopic dermatitis. *Cutis*. 2019;104(3):189–93.
61. Ashbaugh AG, Kwatra SG. Atopic Dermatitis Disease Complications. *Adv Exp Med Biol*. 2017;1027:47–55.
62. Kim J, Kim BE, Ahn K, Leung DYM. Interactions between atopic dermatitis and staphylococcus aureus infection: Clinical implications. *Allergy, Asthma Immunol Res*. 2019;11(5):593–603.
63. Sun D, Ong PY. Infectious Complications in Atopic Dermatitis. *Immunol Allergy Clin North Am [Internet]*. 2017;37(1):75–93.
64. Damour A, Garcia M, Seneschal J, Lévêque N, Bodet C. Eczema Herpeticum: Clinical and Pathophysiological Aspects. *Clin Rev Allergy Immunol*. 2020;59(1).
65. Glatz M, Bosshard PP, Hoetzenecker W, Schmid-Grendelmeier P. The role of malassezia spp in atopic dermatitis. *J Clin Med*. 2015;4(6):1217–28.
66. Strom MA, Fishbein AB, Paller AS, Silverberg JI. Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults. *Br J Dermatol*. 2016;175(5):920–9.
67. Kage P, Zarnowski J, Simon JC, Treudler R. Atopic dermatitis and psychosocial comorbidities – What’s new? *Allergol Sel*. 2020;4(01):86–96.
68. Khalil A, Elesawy BH, Ali TM, Ahmed OM. Bee venom: From venom to drug. *Molecules*. 2021;26(16):1–17.
69. Wehbe R, Frangieh J, Rima M, Obeid D El, Sabatier JM, Fajloun Z. Bee venom: Overview of main compounds and bioactivities for therapeutic interests. *Molecules*. 2019;24(16):1–13.
70. Pucca MB, Cerni FA, Oliveira IS, Jenkins TP, Argemí L, Sørensen C V., et al. Bee Updated: Current Knowledge on Bee Venom and Bee Envenoming Therapy. *Front Immunol*. 2019;10(September):1–15.
71. Kim W. Bee Venom and Its Sub-Components : Characterization, Pharmacology, and Therapeutics. 2021;14–5.
72. Hong J, Lu X, Deng Z, Xiao S, Yuan B, Yang K. How Melittin Inserts into Cell Membrane: Conformational Changes, Inter-Peptide Cooperation, and Disturbance on the Membrane. *Molecules [Internet]*. 2019 May

7;24(9):1775.

73. Lee G, Bae H. Bee venom phospholipase A2: Yesterday's enemy becomes today's friend. *Toxins (Basel)*. 2016;8(2).
74. Soltan-Alinejad P, Alipour H, Meharabani D, Azizi K. Therapeutic Potential of Bee and Scorpion Venom Phospholipase A2 (PLA2): A Narrative Review. *Iran J Med Sci*. 2022;47(4):300–13.
75. Carpena M, Nuñez-Estevez B, Soria-Lopez A, Simal-Gandara J. Bee venom: An updating review of its bioactive molecules and its health applications. *Nutrients*. 2020;12(11):1–27.
76. Shin D, Choi W, Bae H. Bee venom phospholipase A2 alleviate house dust mite-induced atopic dermatitis-like skin lesions by the CD206 mannose receptor. *Toxins (Basel)*. 2018;10(4).
77. Kim DH, Song HS. Atopic Dermatitis-Related Inflammation in Macrophages and Keratinocytes: The Inhibitory Effects of Bee Venom. *J Acupunct Res*. 2019;36(2):80–7.
78. Lee YJ, Oh MJ, Lee DH, Lee YS, Lee J, Kim DH, et al. Anti-inflammatory effect of bee venom in phthalic anhydride-induced atopic dermatitis animal model. *Inflammopharmacology [Internet]*. 2020;28(1):253–63.
79. Oh MJ, Song HS. Anti-Inflammatory Effects of Bee Venom on Phthalic Anhydride-Induced Atopic Dermatitis. *J Acupunct Res*. 2020;37(1):42–8.
80. Park KJ, Song HS. Effect of Bee Venom Pharmacopuncture on Inflammation in Mouse Model of Induced Atopic Dermatitis. *J Acupunct Res*. 2020;37(2):123–7.
81. Kim J, Song HS. Bee Venom Within Liposomes Synergistically Inhibit Atopic Dermatitis in Mice. *J Acupunct Res*. 2022;39(1):40–8.

